Drug intelligence / Profile preview

hawthorn leaf extract

Development stage: Unknown
Lead developer: Jiangxi Qingchun Kangyuan Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Hawthorn leaf extract is a natural botanical product manufactured by Jiangxi Qingchun Kangyuan Pharmaceutical. It is derived from the dried leaves of *Crataegus pinnatifida* (Chinese hawthorn) and is standardized for its flavonoid content. The extract is primarily used for cardiovascular health, where it is reported to reduce blood pressure, increase coronary blood flow, and lower lipid and cholesterol levels. It also possesses antioxidant properties. The product is supplied as a raw material for the pharmaceutical, nutraceutical, and cosmetic industries, with a significant production capacity under GMP standards.

Other names: 山楂叶提取物Hawthorn extractCrataegus pinnatifida leaf extract

Beyond the preview

Go deeper on hawthorn leaf extract.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on hawthorn leaf extract.

Explore the full profile